Amundi
ITOS

Amundi’s iTeos Therapeutics ITOS Stock Holding History

Amundi’s Portfolio ITOS Stock Details ITOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-1,799
Closed -$16.3K – 2034
2023
Q3 		$16.3K Hold
1,799
– – ﹤0.01% 1951
2023
Q2 		$24K Hold
1,799
– – ﹤0.01% 1951
2023
Q1 		$23.8K Hold
1,799
– – ﹤0.01% 1952
2022
Q4 		$34.5K Hold
1,799
– – ﹤0.01% 1743
2022
Q3 		$35K Buy
+1,799
New +$41.4K ﹤0.01% 1710

Other funds holding ITOS

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Amundi's ITOS Position: Q4 2023 in Review

Amundi sold out of iTeos Therapeutics (ITOS) in Q4 2023, closing a stake of 1,799 shares — an estimated $16.3K sold.

Amundi first reported a position in ITOS in Q3 2022 and held it in 5 quarters. The position peaked at $35K in Q3 2022. 137 funds tracked by Wall St. Rank hold ITOS as of Q4 2023.

  • Amundi reported no remaining iTeos Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Amundi sold 1,799 iTeos Therapeutics shares in Q4 2023, an estimated $16.3K.
  • Amundi first reported a position in iTeos Therapeutics in Q3 2022 and held it in 5 quarters.
  • Amundi's iTeos Therapeutics position peaked at $35K in Q3 2022.
  • 137 funds tracked by Wall St. Rank held iTeos Therapeutics as of Q4 2023.

Based on Amundi's 13F filing for Q4 2023, filed 14 Feb 2024.